Primary Biliary Cholangitis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players_Therapeutics_COmpanies.webp)
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Primary Biliary Cholangitis Market Analysis
The global primary biliary cholangitis (PBC) market is projected to grow with a CAGR of nearly 10% over the forecast period. The growth is attributed to the increase in cases of primary biliary cholangitis and increasing R&D investment in the development of new therapeutics for the disease. Due to the recurring nature of the disease currently, there are only a few treatment options available for the disease, primarily liver transplantation. Moreover, regenerative and stem cell therapies are at the nascent stage which will drive the market growth of therapeutics over the forecast period. However, the asymptomatic nature of the disease delays diagnosis and treatment, lack of awareness among the population about the disease and stringent regulatory policies are the factors that are anticipated to hamper the market growth.
Primary Biliary Cholangitis Market Trends
This section covers the major market trends shaping the Primary Biliary Cholangitis Therapeutics Market according to our research experts:
Obeticholic Acid to Grow at Significant Rate
- Presently, there is no total cure for the disease. But, the liver damage can be delayed using the therapeutics. Ocaliva is a semisynthetic bile acid analogue which is used as a primary drug for the treatment of primary biliary cholangitis.
- On the other hand, Ursodeoxycholic acid is a secondary bile acid produced by intestinal bacteria. This shows advanced effects on kidney destruction, but a few percentages of the patient shows intolerance to the drug.
- According to the U.S. Department of Health and Human Services, 65 out of 100,000 women and about 10 of 100,000 men in the United States have primary biliary cholangitis.
- Moreover, factors such as the increase in R&D investments and presence of robust pipeline in for autoimmune diseases, especially primary biliary cholangitis are anticipated to boost the market growth over the forecast period.
North America to Have Significant Growth
Among the regional segments, North America is projected to have significant market growth owing to well-established healthcare infrastructure, presence of key market players and recent product launches. Moreover, the growing number of patients with the primary biliary cirrhosis and growing demand for the therapeutics is anticipated to fuel the market growth over the forecast period. Ocaliva drug was approved in 2016, in Europe and the United States, and had notable initial sales, however, the recent black box warnings from the regulatory authorities have impacted the usage. There is a tremendous need for the development of new therapeutics, and it is taken up by the market players in the region anticipated to boost the regional growth.
Primary Biliary Cholangitis Industry Overview
Global primary biliary cholangitis (PBC) therapeutics market is moderately competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Allergan Inc. and Glenmark Pharmaceuticals among others.
Primary Biliary Cholangitis Market Leaders
Intercept Pharmaceuticals, Inc.
Teva Pharmaceutical
Mylan Inc.
Allergan Inc.
Glenmark Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
_Therapeutics_Conc.webp)
Primary Biliary Cholangitis Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing R&D For Development of New Drug Therapeutics For Primary Biliary Cholangitis
-
4.2.2 Growing Burden of Primary Biliary Cholangitis and Liver Related Disorders
-
-
4.3 Market Restraints
-
4.3.1 Stringent Regulatory Policies
-
4.3.2 Lack of Awareness Regarding Liver Disorders
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug
-
5.1.1 Obeticholic Acid
-
5.1.2 Ursodeoxycholic Acid
-
5.1.3 Others
-
-
5.2 Geography
-
5.2.1 North America
-
5.2.1.1 United States
-
5.2.1.2 Canada
-
5.2.1.3 Mexico
-
-
5.2.2 Europe
-
5.2.2.1 Germany
-
5.2.2.2 United Kingdom
-
5.2.2.3 France
-
5.2.2.4 Italy
-
5.2.2.5 Spain
-
5.2.2.6 Rest of Europe
-
-
5.2.3 Asia-Pacific
-
5.2.3.1 China
-
5.2.3.2 Japan
-
5.2.3.3 India
-
5.2.3.4 Australia
-
5.2.3.5 South Korea
-
5.2.3.6 Rest of Asia-Pacific
-
-
5.2.4 Middle-East and Africa
-
5.2.4.1 GCC
-
5.2.4.2 South Africa
-
5.2.4.3 Rest of Middle-East and Africa
-
-
5.2.5 South America
-
5.2.5.1 Brazil
-
5.2.5.2 Argentina
-
5.2.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Intercept Pharmaceuticals, Inc.
-
6.1.2 Teva Pharmaceutical
-
6.1.3 Mylan Inc.
-
6.1.4 Allergan Inc.
-
6.1.5 Glenmark Pharmaceuticals
-
6.1.6 Eli Lilly and Company
-
6.1.7 Endo International plc
-
6.1.8 Novartis AG
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Primary Biliary Cholangitis Industry Segmentation
Primary biliary cholangitis also known as primary biliary cirrhosis is an autoimmune disease of the liver. This results from the slow and progressive destruction of the biliary cells. Currently, a limited number of therapeutics are approved for the treatment of primary biliary cholangitis.
| By Drug | |
| Obeticholic Acid | |
| Ursodeoxycholic Acid | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Primary Biliary Cholangitis Market Research FAQs
What is the current Primary Biliary Cholangitis (PBC) Therapeutics Market size?
The Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to register a CAGR of 10% during the forecast period (2024-2029)
Who are the key players in Primary Biliary Cholangitis (PBC) Therapeutics Market?
Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Mylan Inc., Allergan Inc. and Glenmark Pharmaceuticals are the major companies operating in the Primary Biliary Cholangitis (PBC) Therapeutics Market.
Which is the fastest growing region in Primary Biliary Cholangitis (PBC) Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Primary Biliary Cholangitis (PBC) Therapeutics Market?
In 2024, the North America accounts for the largest market share in Primary Biliary Cholangitis (PBC) Therapeutics Market.
What years does this Primary Biliary Cholangitis (PBC) Therapeutics Market cover?
The report covers the Primary Biliary Cholangitis (PBC) Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Primary Biliary Cholangitis (PBC) Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Primary Biliary Cholangitis Therapeutics Industry Report
Statistics for the 2024 Primary Biliary Cholangitis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Primary Biliary Cholangitis Therapeutics analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
